MANet: a multi-attention network for automatic liver tumor segmentation in computed tomography (CT) imaging.

Automatic liver tumor segmentation is a paramount important application for liver tumor diagnosis and treatment planning. However, it has become a highly challenging task due to the heterogeneity of the tumor shape and intensity variation. Automatic liver tumor segmentation is capable to establish the diagnostic standard to provide relevant radiological information to all levels of expertise. Recently, deep convolutional neural networks have demonstrated superiority in feature extraction and learning in medical image segmentation. However, multi-layer dense feature stacks make the model quite inconsistent in imitating visual attention and awareness of radiological expertise for tumor recognition and segmentation task. To bridge that visual attention capability, attention mechanisms have developed for better feature selection. In this paper, we propose a novel network named Multi Attention Network (MANet) as a fusion of attention mechanisms to learn highlighting important features while suppressing irrelevant features for the tumor segmentation task. The proposed deep learning network has followed U-Net as the basic architecture. Moreover, residual mechanism is implemented in the encoder. Convolutional block attention module has split into channel attention and spatial attention modules to implement in encoder and decoder of the proposed architecture. The attention mechanism in Attention U-Net is integrated to extract low-level features to combine with high-level ones. The developed deep learning architecture is trained and evaluated on the publicly available MICCAI 2017 Liver Tumor Segmentation dataset and 3DIRCADb dataset under various evaluation metrics. MANet demonstrated promising results compared to state-of-the-art methods with comparatively small parameter overhead.

G6PD diaxBox: Digital image-based quantification of G6PD deficiency.

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common enzymopathy in humans. More than 400 million people worldwide are affected by this genetic condition. Testing for G6PD deficiency before drug administration is essential for patient safety. Rapidly ascertaining the G6PD status of a person is desirable for proper treatment. The device described in this study, the G6PD diaxBOX, was developed to quantify G6PD deficiency using paper-based analytical devices (PADs) and a colorimetric assay. The G6PD diaxBOX is a straightforward, affordable, portable, and instrument-free analytical system. The major components of the G6PD diaxBox are a banknote-checking UV fluorescent lamp and camera that are easy to access and analysis software. When NADPH is generated, it absorbs at UV 340 nm and emits colored light that is detected with the camera. The determined Pearson's coefficient shows that the color intensity measured from the G6PD diaxBOX correlated with G6PD activity level. Also, a Bland-Altman analysis indicated that more than 95% of the measurement error was in the upper and lower boundaries (±2 SD) and the error from the severe and moderate deficiency group was less than ± 1 SD. Therefore, the error from G6PD diaxBOX was within the limit boundary and the overall accuracy was more than 80%. The G6PD diaxBOX facilitates the effective and efficient quantification of G6PD deficiency and as such represents a clinically well-suited, rapid point-of-care test.